Research Topics
| Dan C MaloneSummaryAffiliation: University of Arizona Country: USA Publications
| Collaborators
|
Detail Information
Publications
Identification of serious drug-drug interactions: results of the partnership to prevent drug-drug interactionsDaniel C Malone
Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, PO Box 210207, Tucson, AZ 85721 0207, USA
J Am Pharm Assoc (2003) 44:142-51. 2004..To develop a list of clinically important drug-drug interactions (DDIs) likely to be encountered in community and ambulatory pharmacy settings and detected by a computerized pharmacy system...- Adherence assessment using medication weight in a phase IIb clinical trial of difluoromethylornithine for the chemoprevention of skin cancerLisa M Hess
Arizona Cancer Center, University of Arizona, P O Box 245024, 1515 North Campbell Avenue, 2964A1 Tucson, AZ 85724, USA
Cancer Epidemiol Biomarkers Prev 14:2579-83. 2005..This study evaluates the association between participant self-reported study diary records and the weight of the medication vessel at each study visit, in the setting of a phase IIb topical chemoprevention trial... - An economic analysis of a randomized, controlled, multicenter study of clinical pharmacist interventions for high-risk veterans: the IMPROVE study. Impact of Managed Pharmaceutical Care Resource Utilization and Outcomes in Veterans Affairs Medical CentersD C Malone
University of Colorado Health Sciences Center, School of Pharmacy, Denver, USA
Pharmacotherapy 20:1149-58. 2000..To determine if clinical pharmacists could affect economic resource use and humanistic outcomes in an ambulatory, high-risk population... - Pharmacist workload and pharmacy characteristics associated with the dispensing of potentially clinically important drug-drug interactionsDaniel C Malone
College of Pharmacy, University of Arizona, Tucson 85721, USA
Med Care 45:456-62. 2007..The purpose of this study was to examine pharmacy characteristics that may be associated with dispensed potential DDIs... - Characteristics of older adults who meet the annual prescription drug expenditure threshold for medicare medication therapy management programsGregory W Daniel
University of Arizona, 1295 N Martin, PO Box 210202, Tucson, AZ 85721 0202, USA
J Manag Care Pharm 13:142-54. 2007.... - A budget-impact and cost-effectiveness model for second-line treatment of major depressionDaniel C Malone
Center for Health Outcomes and PharmacoEconomic Research, University of Arizona College of Pharmacy, Tucson, AZ 85721, USA
J Manag Care Pharm 13:S8-18. 2007..Depressed patients who initially fail to achieve remission when placed on a selective serotonin reuptake inhibitor (SSRI) may require a second treatment... - Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis CDaniel C Malone
University of Arizona College of Pharmacy, PO Box 210207, Tucson, AZ 85721, USA
J Manag Care Pharm 11:687-94. 2005.... - Evaluation of a wireless handheld medication management device in the prevention of drug-drug interactions in a Medicaid populationDaniel C Malone
College of Pharmacy, University of Arizona, 1295 N Martin, Tucson, AZ 85721 0202, USA
J Manag Care Pharm 18:33-45. 2012.... - Cost-effectiveness of sibutramine in the LOSE Weight Study: evaluating the role of pharmacologic weight-loss therapy within a weight management programDaniel C Malone
University of Arizona College of Pharmacy, PO Box 210207, Tucson, AZ 85721, USA
J Manag Care Pharm 11:458-68. 2005..The core WMP was a physician-supervised, multidisciplinary program for which each enrollee paid $100 out of pocket... - The role of pharmacoeconomic modeling in evidence-based and value-based formulary guidelinesDaniel C Malone
University of Arizona College of Pharmacy, Tucson, AZ 85721, USA
J Manag Care Pharm 11:S7-10. 2005..To review evidence-based medicine (EBM) in the context of pharmacoeconomic (PE) decision making by health care organizations... - Hydrofluoroalkane-134a beclomethasone as a dominant economic asthma therapyD C Malone
Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona Health Sciences Center, 1703 E Mabel Street, Tucson, AZ 85721 0207, USA
Respir Med 97:1269-76. 2003..The median incremental cost-effectiveness ratio was dollars -5.77 (95% CI: dollars -68.08 to dollars -4.08). The results of this analysis indicate that HFA-BDP was a dominant therapy (more effective, less costly) compared to CFC-BDP... - Can clinical pharmacists affect SF-36 scores in veterans at high risk for medication-related problems?D C Malone
University of Colordao Health Sciences Center, USA
Med Care 39:113-22. 2001..An objective of pharmaceutical care is for pharmacists to improve patients' health-related quality of life (HRQOL) by optimizing medication therapy... - Adherence to ATS guidelines for hospitalized patients with community-acquired pneumoniaD C Malone
College of Pharmacy, University of Arizona, Tucson 85721 0207, USA
Ann Pharmacother 35:1180-5. 2001..METHODs: A retrospective chart review of patients from community hospitals with a diagnosis of pneumonia at discharge admitted from December 1997 to May 1998. Data were collected based on American Thoracic Society (ATS) criteria... - Burden of Alzheimer's disease and association with negative health outcomesDaniel C Malone
College of Pharmacy, University of Arizona, Tucson, AZ 85721 0202, USA
Am J Manag Care 15:481-8. 2009..To examine the association of Alzheimer's disease (AD) with common chronic conditions, acute care events, and risk of hospitalization... - A claims-based Markov model for Crohn's diseaseD C Malone
University of Arizona College of Pharmacy, Tucson, 85721 0202, USA
Aliment Pharmacol Ther 32:448-58. 2010..Crohn's disease is a chronic condition that often presents in early adulthood... - Association of cardiometabolic risk factors and prevalent cardiovascular eventsDan C Malone
College of Pharmacy, University of Arizona, Tucson, Arizona 85721 0202, USA
Metab Syndr Relat Disord 7:585-93. 2009..This study evaluated cardiometabolic risk factors and their relationship to prevalent diagnosis of acute myocardial infarction (AMI) and stroke... - Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care SystemWei Shi Yeh
Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson, Arizona 85721, USA
Pharmacotherapy 27:813-24. 2007.... - Relationship between pharmaceutical services characteristics and exposure rates to drug-drug interactions in Veterans Affairs medical centersMaysaa H Mahmood
PharmaceuticalSciences, College of Pharmacy, University of Arizona, Tucson 5721 0202, USA
Am J Health Syst Pharm 65:1744-9. 2008..The association between the exposure rates of clinically important drug-drug interactions (DDIs) and the structure of pharmaceutical services within the ambulatory care settings of Veterans Affairs medical centers (VAMCs) is discussed... - Potential drug-drug interactions within Veterans Affairs medical centersMaysaa Mahmood
Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona UA, Tucson, AZ 85721 0202, USA
Am J Health Syst Pharm 64:1500-5. 2007..This study assessed the prevalence of 25 clinically important drug-drug interactions (DDIs) in the ambulatory care clinics of the Department of Veterans Affairs medical centers (VAMCs)... - Assessment of potential drug-drug interactions with a prescription claims databaseDaniel C Malone
College of Pharmacy, University of Arizona, 1703 E Mabel, Tucson, AZ 85721, USA
Am J Health Syst Pharm 62:1983-91. 2005..The prevalence of 25 clinically important potential drug-drug interactions (DDIs) in a population represented by the drug claims database of a pharmacy benefit management company (PBM) was studied... - An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed careGrant H Skrepnek
Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, College of Pharmacy, Tucson, AZ 85721, USA
Curr Med Res Opin 21:261-70. 2005..Study design: Retrospective managed care database analysis... - Angiotensin-converting enzyme inhibitor therapy in patients with heart failure enrolled in a managed care organization: effect on costs and probability of hospitalizationJacob Abarca
Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson, Arizona, USA
Pharmacotherapy 24:351-7. 2004..To evaluate the effect of angiotensin-converting enzyme (ACE) inhibitor therapy on risk of hospitalization and resource utilization in patients with heart failure enrolled in a managed care organization... - Development of computerized alerts with management strategies for 25 serious drug-drug interactionsJohn E Murphy
College of Pharmacy, The University of Arizona, Tucson, AZ 85721 0202, USA
Am J Health Syst Pharm 66:38-44. 2009..The development of computerized alerts with management strategies for 25 drug-drug interactions (DDIs) is described... - Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladderYu Ko
Department of Pharmaceutical Sciences, College of Pharmacy, University of Arizona, Tucson, Arizona 85721 0207, USA
Pharmacotherapy 26:1694-702. 2006..To compare the cost-effectiveness of various antimuscarinic agents for the treatment of overactive bladder (OAB)... - Cost-effectiveness analysis of simvastatin and lovastatin/extended- release niacin to achieve LDL and HDL goal using NHANES dataEdward P Armstrong
Department of Pharmacy Practice, Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA
J Manag Care Pharm 10:251-8. 2004..The purpose of this study was to compare 2 regimens achieving simultaneous LDL and HDL goals... - Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measuresLisa M Hess
Arizona Cancer Center, University of Arizona, Tucson, 85724, USA
Ann Pharmacother 40:1280-88. 2006..These measures have focused on improving the accuracy of adherence measures or clarifying the evaluation time frame. As a result, there are many measures used to assess adherence that may or may not be comparable or accurate... - Evaluation of the performance of drug-drug interaction screening software in community and hospital pharmaciesJacob Abarca
Center for Health Outcomes and PharmacoEconomic Research, University of Arizona College of Pharmacy, P O Box 210202 Tucson, AZ 85721 0202, USA
J Manag Care Pharm 12:383-9. 2006..Computerized drug-drug interaction (DDI) screening is widely used to identify potentially harmful drug combinations in the inpatient and outpatient setting... - Workload and availability of technology in metropolitan community pharmaciesGrant H Skrepnek
Center for Health Outcomes and PharmarcoEconomic Research, College of Pharmacy, University of Arizona, 1703 East Mabel Street, Tucson, AZ 85721, USA
J Am Pharm Assoc (2003) 46:154-60. 2006..To assess workload characteristics and the presence of prescription processing technologies within metropolitan community pharmacies in the United States... - Community pharmacy managers' perception of computerized drug-drug interaction alertsJacob Abarca
Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, P O Box 210207, Tucson, AZ 85721 0207, USA
J Am Pharm Assoc (2003) 46:148-53. 2006..To examine community pharmacists' attitudes toward computerized drug-drug interaction (DDI) alerts and identify factors associated with more favorable perceptions of these alerts... - Reasons provided by prescribers when overriding drug-drug interaction alertsAmy J Grizzle
Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson, AZ 85721 0202, USA
Am J Manag Care 13:573-8. 2007..To investigate prescribers' rationales for overriding drug-drug interaction (DDI) alerts and to determine whether these reasons were helpful to pharmacists as a part of prescription order verification... - A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorderEdward P Armstrong
College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA
Curr Med Res Opin 24:1115-21. 2008..To estimate the costs and quality-adjusted life weeks of duloxetine and escitalopram... - Practitioners' views on computerized drug-drug interaction alerts in the VA systemYu Ko
College of Pharmacy, University of Arizona, Drachman B307F, 1295 N Martin, Tucson, AZ 85721 0207, USA
J Am Med Inform Assoc 14:56-64. 2007..To assess Veterans Affairs (VA) prescribers' and pharmacists' opinions about computer-generated drug-drug interaction (DDI) alerts and obtain suggestions for improving DDI alerts... - Longitudinal analysis of the use of etanercept versus infliximab determined from medical chart auditJacob Abarca
University of Arizona College of Pharmacy, Center for Health Outcomes and PharmacoEconomic Research, 1703 E Mabel, P O Box 210207, Tucson, AZ 85721 0207, USA
J Manag Care Pharm 10:538-42. 2004..To describe the dosing of etanercept and infliximab for the treatment of rheumatoid arthritis (RA)... - The impact of nonsteroidal anti-inflammatory drugs on blood pressure, with an emphasis on newer agentsEdward P Armstrong
College of Pharmacy, University of Arizona, Tuczon, AZ 85721, USA
Clin Ther 25:1-18. 2003..Both nonselective and selective nonsteroidal anti-inflammatory drugs (NSAIDs) have been reported to increase blood pressure (BP)... - Incremental effects of concurrent pharmacotherapeutic regimens for heart failure on hospitalizations and costsGrant H Skrepnek
College of Pharmacy, University of Arizona, Tucson, AZ 85721 0207, USA
Ann Pharmacother 39:1785-91. 2005..Inappropriate medication use in patients with heart failure (HF) presents challenges in providing optimal, evidence-based care... - Mirtazapine is associated with less anxiolytic use among elderly depressed patients in long-term care facilitiesMarie E Gardner
College of Pharmacy, The University of Arizona, Tucson, AZ, USA
J Am Med Dir Assoc 5:101-6. 2004..Depression is a common, treatable disorder among nursing facility residents... - Physicians' opinions of a health information exchangeAna Lucia Hincapie
Department of Pharmacy Practice and Science, The Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson, Arizona, USA
J Am Med Inform Assoc 18:60-5. 2011..Arizona Medicaid developed a Health Information Exchange (HIE) system called the Arizona Medical Information Exchange (AMIE)... - Gender and age differences in medications dispensed from a national chain drugstoreMarietta Anthony
The Critical Path Institute, Tucson, Arizona 85718, USA
J Womens Health (Larchmt) 17:735-43. 2008..Our objective was to compare sex and age differences in the medications dispensed in pharmacies from a large national drugstore chain... - Concordance of severity ratings provided in four drug interaction compendiaJacob Abarca
Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson 85721-0207, USA
J Am Pharm Assoc (2003) 44:136-41. 2004..A concerted effort to identify DDIs of the highest clinical importance is needed to design effective strategies to avoid and manage them... - Accuracy of adverse-drug-event reports collected using an automated dispensing systemAndrew V Romero
University Medical Center, Tucson, AZ, USA
Am J Health Syst Pharm 62:1375-80. 2005..2% (95% CI, 86.1-104.4%) and 72.7% (95% CI, 46.4-99.1%), respectively. CONCLUSION: A Pyxis ADE reporting mechanism using the tracer drugs D50 and naloxone increased the overall reporting of ADEs... - Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapyScott L Charland
School of Pharmacy, University of Colorado, 258 Leland Creek Circle, Box 1941, Winter Park, CO 80482 1941, USA
Curr Med Res Opin 26:365-75. 2010..With numerous treatment options for managing dyslipidemia, it is important to evaluate agents that result in the greatest reduction of CVEs... - Profiling quality of diabetes care in a Veterans Affairs Healthcare SystemVijay N Joish
The University of Arizona, Tucson, USA
Am J Med Qual 19:112-20. 2004.... - Development and validation of a diabetes mellitus severity index: a risk-adjustment tool for predicting health care resource use and costsVijay N Joish
Department of Pharmacotherapy, College of Pharmacy, Pharmacotherapy Outcomes Research Center, University of Utah, Salt Lake City, 84108, USA
Pharmacotherapy 25:676-84. 2005..To develop and validate a diabetes mellitus-specific risk-adjustment tool--the diabetes severity index (DSI)--to assist in predicting health care costs and resources within populations of patients with diabetes... - Health services use and health care costs of obese and nonobese individualsMarsha A Raebel
Clinical Research Unit, Kaiser Permanente of Colorado, Denver, CO 80237, USA
Arch Intern Med 164:2135-40. 2004..Obesity has clinical and economic consequences. Few studies have compared health care resource utilization between age- and sex-matched obese and nonobese persons... - Performance of drug-drug interaction software for personal digital assistantsNatalie A Perkins
El Rio Health Center Special Immunology Associates, Tucson, AZ, USA
Ann Pharmacother 40:850-5. 2006..In addition, ePocrates Rx is updated regularly and is easily accessible on the Internet at no cost... - A cost-benefit analysis of vision screening methods for preschoolers and school-age childrenVijay N Joish
Department of Pharmacy Practice and Sciences, College of Pharmacy, The University of Anzona, Tucson 85721-0284, USA
J AAPOS 7:283-90. 2003..CONCLUSIONS: Based on the best available data, the net benefit of PS in 3 to 4 year old preschool children is greater than VAS in children 7 to 8 years of age, PS in toddlers, and VAS in children 3 to 4 years of age... - Fluticasone is associated with lower asthma-related costs than leukotriene modifiers in a real-world analysisEdward P Armstrong
College of Pharmacy, University of Arizona, Tucson 85721, USA
Pharmacotherapy 22:1117-23. 2002..0014). CONCLUSION: These results suggest that fluticasone is associated with lower asthma-related costs than leukotriene modifiers... - Pharmacy students' ability to identify potential drug-drug interactionsKim R Saverno
University of Arizona College of Pharmacy, USA
Am J Pharm Educ 73:27. 2009..To evaluate the ability of third- and fourth-year pharmacy students to identify clinically significant drug-drug interactions (DDIs).. - Consumer understanding and satisfaction associated with a 3-tier prescription drug benefitBridget M Olson
Eli Lilly and Company, 9872 Saskatchewan Ave, San Diego, CA 92129, USA
J Manag Care Pharm 11:480-92. 2005..The purpose of this research was to investigate consumer understanding and satisfaction associated with a 3-tier prescription drug benefit among users of the prescription drug benefit... - Comparison of peptic-ulcer drug use and expenditures before and after the implementation of a government policy to separate prescribing and dispensing practices in South KoreaEui Kyung Lee
Division of Health Research, Korea Institute for Health and Social Affairs, Seoul, South Korea
Clin Ther 25:578-92. 2003..It was hoped that this policy would promote the rational use of medications and reduce medication expenditures, which accounted for approximately 30% of the total health care expenditures before the implementation of SPD... - Use of salmeterol with and without concurrent use of inhaled corticosteroids and the risk of asthma-related hospitalization among patients with asthmaMeng Ting Wang
School of Pharmacy, National Defense Medical Center, Taipei, Taiwan, Republic of China
Curr Med Res Opin 24:859-67. 2008..Studies evaluating the safety of salmeterol are inconclusive, which might be the result from not taking into account the impact of concomitant inhaled corticosteroids (ICS)... - Prescribers' knowledge of and sources of information for potential drug-drug interactions: a postal survey of US prescribersYu Ko
Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore
Drug Saf 31:525-36. 2008.... - Gastrointestinal disease control after histamine2-receptor antagonist dose modification for renal impairment in frail chronically ill elderly patientsThomas E Lackner
University of Minnesota, College of Pharmacy and Institute for the Study of Geriatric Pharmacotherapy, Minneapolis, USA
J Am Geriatr Soc 51:650-6. 2003..To determine whether histamine2-receptor antagonist (H2RA) dose modified for renal impairment affects gastrointestinal (GI) disease control... - Using indirect comparisons in pharmacoeconomic studies--time for implementationDaniel C Malone
Clin Ther 29:2454-5. 2007 - Studying pharmaceutical care: difficult but necessaryDale B Christensen
University of North Carolina School of Pharmacy, Chapel Hill, USA
J Am Pharm Assoc (2003) 43:S36-7. 2003..Demonstrating changes in patient satisfaction with providers and in health-related quality of life is difficult...